Surgical treatment of stage III thymic tumors: a multi-institutional review from four Italian centers☆

Abstract

Multimodality treatment of stage III thymic tumors achieved good survival. Radical surgery, even at recurrence, seems to be the most important prognostic factor.

Long-Term Outcomes of Recurrent Thymoma

“…There may be statistical significance accompanied by the increase of samples. Our data is consistent with the outcomes of previous studies that reoperation might result in better survival than non-surgery treatment, especially when complete resection was possible [3,4,[6][7][8]10,12,[16][17][18][19][20][21]. A meta- advanced stage (III/IV) thymoma or incomplete resection [4,8,[28][29][30][31][32], theoretically, adjuvant treatment may also improve the outcomes of recurrent thymoma.…”

“…Whereas, unlike the previous studies [3,4,[6][7][8]12,[16][17][18][19][20][21], we observed that much high percent (71.4%) of patients who underwent reoperation received adjuvant chemotherapy, radiotherapy, or chemoradiotherapy, which may improve the treatment outcomes of recurrent thymoma and confound the benefit of reoperation. Based on that adjuvant treatment can improve the outcomes of patients who have median survival interval after recurrence of the chemotherapy group was higher compared with the group of patients without retreatment, but no statistical significance (P=0.062).…”

Management of large mediastinal masses: surgical and anesthesiological considerations

“…Of these great vessels, the SVC is the most commonly affected (57,58), with varying extent of involvement, ranging from partial compression or invasion, to the development of a SVC syndrome (59). The exact incidence of SVC involvement in mediastinal tumors is unknown, due to the relative rareness of this pathology.…”

Multimodality therapy for locally-advanced thymic epithelial tumors: where are we now?

“…Also, the overall survival (OS) and the cancer free survival (CFS) decrease in advanced stage TETs, especially after incomplete resections, while the recurrence rate increases in stage III-IV TETs and in more aggressive histological tumor subtypes (1,(11)(12)(13)(14).…”

“…Furthermore, more than 50% of these patients may develop tumor recurrences after surgery and postoperative RT (12)(13)(14) being pleura, pericardium, diaphragm and lung the most common sites of tumor relapses. Also, the overall survival (OS) and the cancer free survival (CFS) decrease in advanced stage TETs, especially after incomplete resections, while the recurrence rate increases in stage III-IV TETs and in more aggressive histological tumor subtypes (1,(11)(12)(13)(14).…”